Refine
Year of publication
Document Type
- Article (1111)
- Doctoral Thesis (728)
- Book (46)
- Preprint (32)
- Contribution to a Periodical (14)
- Conference Proceeding (11)
- Report (11)
- Review (9)
- diplomthesis (3)
- Part of a Book (2)
Has Fulltext
- yes (1973) (remove)
Is part of the Bibliography
- no (1973)
Keywords
- crystal structure (37)
- Crystal Structure (25)
- Synthesis (15)
- ESR Spectra (14)
- RNA (14)
- NMR-Spektroskopie (12)
- hydrogen bonding (11)
- IR Spectra (10)
- NMR spectroscopy (10)
- RNS (9)
Institute
- Biochemie und Chemie (1973) (remove)
Background: Simple peak-picking algorithms, such as those based on lineshape fitting, perform well when peaks are completely resolved in multidimensional NMR spectra, but often produce wrong intensities and frequencies for overlapping peak clusters. For example, NOESY-type spectra have considerable overlaps leading to significant peak-picking intensity errors, which can result in erroneous structural restraints. Precise frequencies are critical for unambiguous resonance assignments.
Results: To alleviate this problem, a more sophisticated peaks decomposition algorithm, based on non-negative matrix factorization (NMF), was developed. We produce peak shapes from Fourier-transformed NMR spectra. Apart from its main goal of deriving components from spectra and producing peak lists automatically, the NMF approach can also be applied if the positions of some peaks are known a priori, e.g. from consistently referenced spectral dimensions of other experiments.
Conclusions: Application of the NMF algorithm to a three-dimensional peak list of the 23 kDa bi-domain section of the RcsD protein (RcsD-ABL-HPt, residues 688-890) as well as to synthetic HSQC data shows that peaks can be picked accurately also in spectral regions with strong overlap.
Synthese, Reaktivität und strukturelle Vielfalt im Festkörper von Ferrocenylboranen und -boraten
(2013)
Bispezifische transmembrane Antikörperfragmente zur Inhibierung von ErbB-Wachstumsfaktor-Rezeptoren
(2014)
Der epidermale Wachstumsfaktor-Rezeptor (EGFR) und das ErbB2 Molekül sind Mitglieder der ErbB-Rezeptortyrosinkinase-Familie. Die Bindung von Peptidliganden an die extrazelluläre Domäne (ECD) von EGFR führt zu einer Konformationsänderung, die den Dimerisierungs-kompetenten Zustand des Rezeptors stabilisiert und eine Homodimerisierung oder Heterodimerisierung mit anderen ErbB-Rezeptoren erlaubt. ErbB2 liegt dagegen ohne Ligandenbindung dauerhaft in einer Dimerisierungskompetenten Konformation vor. Die Rezeptordimerisierung stimuliert die intrazelluläre Kinaseaktivität, was zu einer Autophosphorylierung distinkter Tyrosine im C-terminalen Schwanz der Rezeptoren führt. Diese Phosphotyrosine dienen als Bindungsstellen unterschiedlicher intrazellulärer Substrate und Adaptorproteine, die Zellwachstums-, Migrations- und Überlebens-fördernde Signalkaskaden auslösen. Eine Über- oder Fehlfunktion dieser Rezeptoren wurde in vielen Karzinomen epithelialen Ursprungs sowie in Glioblastomen beschrieben und mit einem aggressiven Krankheitsverlauf in Verbindung gebracht.
Der therapeutische Antikörper Cetuximab inhibiert das Tumorwachstum, indem er an die ECD von EGFR bindet und dabei die Ligandenbindung und Rezeptoraktivierung unterbindet. Dieselben Eigenschaften weist das single chain fragment variable (scFv) 225 auf, das die gleiche Antigenbindungsdomäne besitzt. Ein weiteres scFv-Antikörperfragment, scFv(30), wurde in vorangegangenen Arbeiten der Gruppe aus einer scFv-Bibliothek isoliert und bindet als zytoplasmatisch stabil exprimierbares Molekül an die intrazelluläre Domäne (ICD) des EGFR.
Im ersten Teil dieser Arbeit wurde das bislang unbekannte Epitop des scFv(30) Antikörperfragments mittels Peptid-Spotting Experimenten bestimmt. Die Bindungsstelle des scFv(30) Proteins wurde dabei am C-terminalen Ende der EGFR Sequenz lokalisiert und umfasst die Aminosäuresequenz GIFKGSTAE (AS 1161-1169 des reifen EGFR Proteins).
Die Expression von Antikörperfragmenten als sogenannte Intrabodies in Tumorzellen stellt einen wirkungsvollen Ansatz zur selektiven Interferenz mit wichtigen physiologischen und pathophysiologischen Prozessen dar. Im zweiten Teil der vorgelegten Arbeit wurde das EGFR-ECD-spezifische Antikörperfragment scFv(225) über eine Transmembrandomäne und eine flexible Gelenkregion mit dem EGFR-ICD-spezifischen scFv(30) Molekül zu einem neuartigen bispezifischen Antikörper verbunden. Die konstitutive Expression dieses 225.TM.30 Intrabodies und der monospezifischen Variante 225.TM nach lentiviraler Transduktion von EGFR-überexprimierenden MDA MB468 und A431 Tumorzellen resultierte in einer substanziellen Reduktion der EGFR-Oberflächenexpression und einer Blockierung der Liganden-induzierten EGFR-Autophosphorylierung, begleitet von einer deutlichen Inhibition des Zellwachstums. Eine weitere Analyse der 225.TM.30-induzierten molekularen Prozesse in diesen Tumorzellen im Vergleich zu den beiden monospezifischen Varianten 225.TM und TM.30 erfolgte mittels eines Tetracyclin-induzierbaren Expressionssystems. Dazu wurden A431, MDA-MB468 und EGFR-negative MDA-MB453 Zellen zunächst mit retroviralen Vektorpartikeln transduziert, die für den optimierten reversen Tetracyclin-kontrollierten Transaktivator (M2) kodieren. Anschließend erfolgte die Tansduktion mit retroviralen transmembranen Antikörperkonstrukten, kontrolliert von einem Tetracyclin-induzierbaren Promoter (T6). Die Doxycyclin (Dox)-induzierte Expression von 225.TM.30 und 225.TM bestätigte die im konstitutiven Expressionssystem beobachteten Ergebnisse. TM.30-exprimierende Zellen zeigten dagegen keinen Unterschied in der Oberflächenexpression oder Aktivierbarkeit von EGFR zu parentalen Zellen, wiesen aber dennoch eine deutliche Inhibition des Wachstums auf. Konfokale Laserscanning Mikroskopie Studien zeigten eine Co-Lokalisation von 225.TM und EGFR hauptsächlich an der Zelloberfläche, während 225.TM.30 und TM.30 im endoplasmatischen Retikulum detektiert wurden und EGFR in diesem Kompartiment festhielten. Die TM.30/EGFR-Komplexe im ER könnten eine ER-Stress-Antwort auslösen und damit das reduzierte Wachstum TM.30-exprimierender Zellen erklären. Tatsächlich wurden in MDA MB468/M2/iTM.30 und A431/M2/iTM.30 Zellen erhöhte Proteindisulfidisomerase (PDI) und teilweise GRP78/BiP Proteinmengen detektiert, die auf eine ER-Stress-Antwort hindeuten. Das bispezifische 225.TM.30 Molekül vereinte die Eigenschaften der monospezifischen Antikörpervarianten. Es hielt wie TM.30 Anteile des EGFR im ER zurück und war wie 225.TM in der Lage, die EGFR-Oberflächenexpression zu reduzieren und die EGFR-Autophosphorylierung zu inhibieren.
Die Expression der drei transmembranen Antikörper in EGFR-negativen MDA-MB453/M2 Zellen hatte dagegen keinen Einfluss auf das Wachstum dieser Zellen, was die EGFR-Spezifität der vorgestellten Moleküle unterstreicht.
Im letzten Teil der vorgelegten Arbeit wurde die scFv(225) Domäne in 225.TM.30 gegen das ErbB2-ECD-spezifische scFv(FRP5) Molekül ausgetauscht, und somit ein ErbB2-ECD- und EGFR-ICD-spezifischer Intrabody generiert (5.TM.30). Nach der Dox-induzierten Expression des 5.TM.30 Moleküls in EGFR- und/oder ErbB2-exprimierenden Tumorzellen wurde die Funktionalität beider Bindungsdomänen verifiziert. Die 5.TM.30 Expression resultierte dabei in ErbB2-positiven Tumorzellen in einer verringerten Oberflächen- und Gesamtexpression von ErbB2 und in EGFR-positiven Zellen in einer Reduktion der EGFR-Gesamtproteinmenge. Dies lässt auf eine erhöhte, 5.TM.30-induzierte Degradation der beiden Rezeptoren schließen. Die Expression des 5.TM.30 Proteins führte zudem zu einer Inhibition des Wachstums EGFR- und/oder ErbB2-positiver Zellen. Weiterhin wurde auch in 5.TM.30-exprimierenden MDA-MB468/M2 Zellen, wie für 225.TM.30 und TM.30 beschrieben, eine Co-Lokalisation des transmembranen Antikörperfragments mit EGFR im ER gezeigt.
Die in dieser Arbeit vorgestellten Ergebnisse weisen erstmals die Funktionalität von membranverankerten mono- und bispezifischen Antikörpermolekülen als Intrabodies nach, und zeigen ihr Potenzial zur gerichteten Interferenz mit der Wachstumsfaktor-abhängigen Signaltransduktion. Durch den Austausch der extra- und intrazellulären Antikörperdomänen könnte diese Strategie ebenso zur Analyse oder Blockade weiterer Signalmoleküle und Signalkomplexe eingesetzt werden.
Die Idee photolabile Schutzgruppen zur temporären Inaktivierung von Biomolekülen zu verwenden, um deren Funktion dann in einem biologischen System präzise orts- und zeitaufgelöst wieder zu aktivieren und so biologische Prozesse genau steuern zu können, wurde erstmals Ende der 1970er Jahre von J. W. Engels und von J. F. Hoffman verfolgt. Seit diesen ersten Arbeiten im Bereich des „Cagings“ wurde in den vergangenen Jahrzehnten eine Vielzahl von Arbeiten auf diesem Gebiet veröffentlicht und mit nahezu alle wichtigen Klassen von Biomolekülen wurden Caging-Experimente durchgeführt. Das Caging von Nukleinsäuren ist noch ein recht neues Feld. Es gab aber aufgrund der Beteiligung von Nukleinsäuren an vielen zentralen zellulären Prozessen im letzten Jahrzehnt ein enorm gesteigertes Interesse an lichtinduzierbaren Nukleinsäuren, vornehmlich zur lichtgesteuertem Genregulation. Der Arbeitskreis von Prof. Heckel befasst sich unter anderem mit dem Caging von Nukleinsäuren, wobei die zentrale Strategie im Anbringen der photolabilen Schutzgruppen an den Nukleobasen besteht. Dies hat den Hintergrund, dass auf diese Art und Weise die Wechselwirkung mit anderen Strängen durch Störung der Watson-Crick-Basenpaarung verhindert werden kann. Die Watson-Crick-Basenpaarung ist das zentrale Element für die Funktionalität nahezu aller Nukleinsäure-vermittelter Prozesse. In den vergangenen Jahren konnte mit dieser Strategie unter anderem erfolgreich die Aktivität von siRNAs und Aptameren mit Licht kontrolliert werden. Alle vier Projekte, welche in dieser Arbeit verfolgt wurden, befassten sich mit dem Caging von Nukleinsäuren. ...
In the past century, scientists have realized that venoms are a source of a number of natural substances presenting a wide range of pharmacological properties and often displaying a high specificity for their targets. Thus, the field of toxinology came into being, which is defined as the study of toxic substances of biological origin. Toxins are found in a wide variety of animals, including fish, cone snails, scorpions, snakes, and even some mammals. To be classified as venom, these must contain substances, i.e. toxins, which disturb physiological processes and must be deliberately delivered to the target animal. Snakes have evolved one of the most sophisticated mechanisms for venom delivery. Envenomation by snakebite can induce and inhibit aggregation/agglutination of platelets as well as inhibit/activate hemostasis, but also disrupt other physiological functions via neurotoxins and angioneurin growth factors. Snake venoms contain a substantial amount of C-type lectin-related proteins (CLRPs) which are known to function, notably, as integrin inhibitors. CLRPs are heterodimers composed of homologous α and β subunits which can assemble either covalently or noncovalently to oligomers, resulting in αβ, (αβ)2 and (αβ)4 structures. Some of the main targets of CLRPs are membrane receptors, coagulation factors, and proteins essential to hemostasis. The platelet collagen receptors GPVI and α2β1 integrin as well as the von Willebrand factor receptor GPIb play important roles in platelet activation and aggregation and are considered main targets of antithrombotic drugs. In this thesis, the integrin α2β1 is particularly considered as it is the sole collagen-binding integrin on platelets. Reduced expression of this platelet receptor results in dysfunction of platelet responses. Equivalently, overexpression of α2β1 integrin results in an increased risk of thrombosis. As a result, selective inhibitors of the collagen-α2β1 interaction could give rise to effective antithrombotic drugs. Integrins are large receptors which mediate cell-cell contacts and the binding of cells to the extracellular matrix (ECM). Therefore, they play a role in physiological processes, e.g. hemostasis and immunity, as well as in pathological processes, e.g. tumor angiogenesis and atherosclerosis. 18 α and 8 β integrin subunits, with nine α subunits containing an additional A domain, associate non-covalently to form 24 heterodimers with distinct binding specificities. Integrin collagen receptors are a subclass of four receptors which all utilize the β1 subunit. The α2β1 integrin is a collagen-binding receptor expressed not only on platelets, but also on endothelial and epithelial cells. Consequently, this integrin is also essential for cell adhesion and migration playing a role in angiogenesis as well as tumor metastasis. To date, there are five known antagonists of α2β1 integrin: EMS16, rhodocetin, vixapatin, and most recently rhinocetin and flavocetin-A. The first four have been shown to be specific for the integrin α2A domain, the major collagen-binding domain. All these antagonists are CLRPs and present new leads for drug design. In the past few years, many insights into the structure and function of rhodocetin were obtained. Monoclonal antibodies proved to be advantageous in disclosing this information, making them not only useful as therapeutic agents, but also as tools for protein characterization. The venom of the Vipera palaestinae snake was recently shown to contain an α2β1 integrin inhibitor, which prevented the integrin from binding collagen. This inhibitor, called vixapatin, was the initial focus of this dissertation. Vixapatin’s interaction with the α2β1 integrin needed further characterization on a molecular and cellular level to assess its medical potential and monoclonal antibodies were to be used as a tool. Originally, vixapatin had been isolated by reversed-phase high-performance liquid chromatography. To avoid the stringency of this method, for this study, it was replaced with gentler chromatographic methods. First, the α2β1 integrin inhibitor was isolated from the crude snake venom with affinity chromatography using the α2A domain as bait, establishing a method to quickly screen venoms for α2β1-binding proteins which affect the collagenintegrin interaction. The applicability of this method to other snake venoms was shown by isolating an α2A domain-specific toxin from the venom of Trimeresurus flavoviridis. To allow further characterization of both these toxins, gel filtration and ion exchange chromatography were employed to purify the protein without the α2A domain. These classical protein purification methods resulted in similar separation patterns of both the V. palaestinae and T. flavoviridis venom proteins. Purified proteins exhibiting the potential of inhibiting integrinbinding to collagen were analyzed by two-dimensional gel electrophoresis. Both VP-i and flavocetin-A, the integrin inhibitors from V. palaestinae and T. flavoviridis, respectively, were shown to have more complex structures than was evident from the purification. Each consisted of four low-molecular-weight proteins which assembled into two bands (for VP-i) or one single band (for flavocetin-A) under non-reducing conditions. Mass spectrometry analyses revealed VP-i to belong to the family of CLRPs, just like vixapatin does. However, these two proteins differed in their primary sequences and only showed homology to one another. The toxin purified from T. flavoviridis revealed this toxin to be flavocetin-A, a heterodimeric CLRP which had so far only been shown to have GPIb-binding activity. At the time of flavocetin-A’s purification, flavocetin-B was co-purified; flavocetin-B consists of the same two α and β subunits, plus an additional γ subunit. As no sequence information is known to date for the γ subunit, it may be one of the additional proteins purified here, along with an additional δ subunit. Therefore, the toxin isolated here may actually consist of four different subunits forming a tetramer of two different heterodimers, generating an (αβ)2(γδ)2 structure. This proposed (αβ)2(γδ)2 flavocetin-A structure has binding sites for both α2β1 integrin and GPIb, with no sterical overlap, as shown by affinity chromatography using the α2A domain and the extracellular domain of the GPIb receptor. The potential of VP-i and flavocetin-A to inhibit integrin-binding to type I collagen was shown during purification: Both toxins efficiently bind to the integrin α2A domain; also, VP-i and vixapatin bind to the A domain with the same affinity. Surface plasmon resonance showed the interaction of flavocetin-A with the α2β1 integrin to be extremely strong and association to be very fast. Furthermore, both toxins were shown to inhibit binding of the wildtype integrin to collagen: VP-i and flavocetin-A acted antagonistically on cell adhesion and cell migration. Initially, the interaction between VP-i and α2β1 integrin was to be further characterized with the help of monoclonal antibodies. However, this proved problematic, the procedure requiring various optimizations. Although, after expert consultation, some monoclonal antibodies could be obtained, the cells were extremely sensitive and gave unsatisfactory results when tested as detection tools in Western blot and immunoassays. Concluding, two novel α2β1 integrin inhibitors were discovered: VP-i and flavocetin-A, which were purified using the same procedure and which have similar functions. Both are Ctype lectin-related proteins which effectively inhibit cell adhesion and migration. This underlines that nature has instrumentalized CLRPs to specifically inhibit α2β1 integrin. Further characterization of VP-i and flavocetin-A will be able to provide leads for future drug development.
Plants absorb sunlight via photosynthetic pigments and convert light energy intochemical energy in the process of photosynthesis. These pigments are mainly bound to antenna protein complexes that funnel the excitation energy to the photosynthetic reaction centres. The peripheral antenna of plant photosystem II (PSII) consists of the major light-harvesting complex of PSII (LHC-II) and the minor LHCs CP29, CP26 and CP24. Light intensity can change frequently and plants need to adapt to high-light conditions in order to avoid photodamage. When more photons are absorbed than can be utilised by the photosynthetic machinery, excessive excitation energy is dissipated as heat by short-term adaptation processes collectively known as non-photochemical quenching (NPQ). A decrease in PSII antenna chlorophyll (Chl) fluorescence yield and a reduction in the average Chl fluorescence lifetime are associated with NPQ. The main component of NPQ is the so-called energy-dependent quenching (qE), and it is triggered by the rapid drop in thylakoid lumenal pH resulting from the plant’s photosynthetic activity. This process is thought to take place at the PSII antenna complexes, which therefore not only capture and transfer light energy but are also involved in balancing the energy flow. The decrease in lumenal pH acivates the enzyme violaxanthin de-epoxidase (VDE), which converts the xanthophyll violaxanthin (Vio) into zeaxanthin (Zea) in the xanthophyll cycle. In addition, the PSII subunit PsbS was discovered to be essential for qE by screening qE-deficient Arabidopsis thaliana mutants. This membrane protein is considered a member of the LHC superfamily, which also includes LHC-II and the minor LHCs. Previous studies on PsbS isolated either from native source or refolded in vitro have produced inconsistent results on its pigment binding capacity. Interestingly, a pH-dependent change in the quaternary structure of PsbS under high light conditions has been reported. This observed dimer-tomonomer transition very likely follows the protonation of lumenal glutamates upon the drop in pH and is accompanied by a change in PSII supercomplex localisation. PsbS dimers are preferentially found in association with the PSII core, whereas PsbS monomers co-localise with LHC-II.Despite the identification of !pH, Zea and PsbS as key players in qE, both the nature of the quencher(s) as well as the underlying molecular mechanism leading to excess energy dissipation still remain unknown. Several models have been put forward to explain the reversible switch in the antenna from an energy-transmitting to a quenched state. Proposals include a simple pigment exchange of Vio for Zea, and aggregation or an internal conformational change of LHC-II. Charge transfer (CT)quenching in the minor LHCs or quenching by carotenoid dark state (Car S1)-Chl interactions have also been suggested. However, none of these qE models has so far been capable of accommodating all the physiological observations and available experimental data. Most importantly, the function of PsbS remains an enigma. A recent qE model suggested that monomerisation of PsbS enables the protein to transiently bind a carotenoid and form a quenching unit with a Chl of a PSII LHC. In view of the various proposed qE mechanisms, this thesis aimed at understanding the interplay of the different qE components and the contribution of the PSII subunits LHC-II, the minor LHCs and PsbS to qE. The initial approach was to investigate the properties of the PSII subunits in the most simple in vitro model system, namely in detergent solution. For this purpose, LHC-II was isolated either from native source or refolded from recombinantly produced protein. Investigation of the minor LHCs and PsbS required heterologous expression and refolding. In addition, experiments were performed on aggregated LHC-II. Aggregates of LHC-II have been used as a popular model system for qE because they exhibit highly quenched Chl fluorescence. At the final stage of this doctoral work, a more sophisticated model system to approximate the thylakoid membrane was developed by reconstitution of the PSII subunits LHC-II and PsbS into liposomes. This system not only allowed for investigation of these membrane proteins in their native environment, but also for mimicking the xanthophyll cycle by distribution of Zea within the membrane as well as !pH by outside buffer exchange. The role of Zea in qE was first investigated with detergent solubilised antenna proteins. The requirement of this xanthophyll for qE is well-known, but the specific contribution to the molecular quenching mechansim is unclear. Previous work had shown that replacement of Vio for Zea in LHC-II was not sufficient to induce Chl fluorescence quenching in Zea-LHC-II, as suggested by the so-called molecular gearshift mechanism. However, by means of selective two-photon excitation spectroscopy, an increase in electronic interactions between Car S1 and Chls was observed for LHC-II upon lowering the pH of the detergent buffer. Electronic Car S1-Chl coupling became even stronger when Zea-LHC-II was probed. The extent of Car S1-Chl coupling correlated directly with the extent of Chl fluorescence quenching, in a similar way as observed previously in live plants under high-light conditions. However, very similar results were obtained with LHC-II aggregates. This implied that the increase in electronic interactions and fluorescence quenching was independent of Zea and low pH. Further experiments on aggregates of LHC-II Chl mutants indicated that the targeted pigments were also not essential for the observed effects. It is proposed that the same molecular mechanism causes an increase in electronic Car S1-Chl interactions and Chl fluorescence quenching in Zea-LHC-II at low pH as well as in aggregated LHC-II. Most likely, surface exposed pigments form random quenching centres in both cases. On the other hand, it was possible that Zea could act as a direct quencher of excess excitation energy in the minor LHCs. However, enrichment of refolded CP29, CP26 and CP24 with Zea did not lead to a change in the Chl excited state lifetime. Formation of a carotenoid radical cation, previously implied in CT quenching, was also not observed, although artificial generation of such a radical cation was principally possible as shown for CP29. During the course of this work, a study reporting the formation of Zea radical cations in minor LHCs was published. Therefore, Zea-enriched minor LHCs were again investigated on the experimental apparatus used in the reported study. Indeed, the presence of at least one carotenoid radical cation for each minor complex was detected. It is suggested that either the preparation method of incubating the refolded minor LHCs with Zea in contrast to refolding the complexes with only Zea and lutein causes the observed differences or that the observed spectral radical cation signatures are due to experimental artifacts. While the experiments with LHC-II and the minor LHCs gave useful insights into the putative qE mechanism, the quencher site and the mode of action of Zea could still not be unambiguously identified. Most importantly, these studies could not explain the function of the qE keyplayer PsbS. Therefore, the focus of the work was shifted to PsbS protein production, purification and characterisation. In view of inconsistent reports on the pigment binding capacity of this PSII subunit, refolding trials with and without photosynthetic pigments were conducted. The formation of a specific pigmentprotein complex typical for other LHCs was not observed and neither was the earlier reported “activation” of Zea for qE by binding to this protein. Nevertheless, PsbS refolded without pigments displayed secondary structure content in agreement with previous studies, indicating pigment-independent folding. Reconstitution of pigmentfree, refolded PsbS into liposomes confirmed that the protein is stable in the absence of pigments. Zea distributed in PsbS-containing liposomes also showed no spectral alteration that would indicate its “activation”. With the ability to reconstitute PsbS, it was then possible to proceed to modelling qE in a proteoliposome system. For this purpose, PsbS was co-reconstituted with LHC-II, which has been reported to interact with PsbS. One-photon excitation (OPE) and two-photon excitation (TPE) spectroscopy measurements were performed on LHC-II- and LHC-II/PsbS-containing liposomes. This enabled both quantification of Chl fluorescence quenching as well as determination of the extent of electronic Car S1-Chl interactions. The effect of Zea was investigated by incorporating it in the proteoliposome membrane. It was shown that Zea alone was not able to induce significant Chl fluorescence quenching when only LHC-II was present. However, when LHC-II and PsbS were co-reconstituted, pronounced Chl fluorescence quenching and an increase in electronic Car S1-Chl interactions were observed and both effects were enhanced when Zea was present. Western blot analysis indicated the presence of a LHC-II/PsbS-heterodimer in these proteoliposomes. In addition to the OPE and TPE measurements, the average Chl fluorescence lifetime was determined in detergent-free buffer at neutral pH and directly after buffer exchange to low pH. No significant changes in the average lifetime were observed for LHC-II proteoliposomes when either Zea was present or after exchange for low pH buffer. This indicated that Zea alone cannot act as a direct quencher, which concurs with the OPE measurements. Moreover, the complex was also properly reconstituted as no aggregation or significant Chl fluorescence quenching were observed. The average lifetime was not significantly affected in LHC-II/PsbS-proteoliposomes, independent of Zea or pH. However, a shortlived component in the presence of a long-lived component was not resolvable with the time resolution of the fluorescence lifetime apparatus.
Implications for qE model systems and the in vivo quenching mechanism are discussed based on the experiments in detergent solution, on LHC-II aggregates and with the proteoliposome model system.